Gene therapy using herpes simplex virus-based vectors

Histology and Histopathology

Volumn 15, Issue 4, 2000, Pages 1253-1259

  Latchman, D S ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Gene therapy; Herpes simplex virus; Neurological diseases; Virus vectors

Indexed keywords

BETA GALACTOSIDASE; GREEN FLUORESCENT PROTEIN; HEAT SHOCK PROTEIN; VIRUS PROTEIN;

DNA TRANSFECTION; GENE EXPRESSION; GENE INSERTION; GENE TARGETING; GENE THERAPY; HERPES SIMPLEX VIRUS; HUMAN; NERVE CELL; NEUROLOGIC DISEASE; NONHUMAN; RECOMBINANT PLASMID; REVIEW; VIRUS GENOME; VIRUS INACTIVATION; VIRUS LATENCY; VIRUS RECOMBINATION; VIRUS VECTOR;

ANIMAL; GENE THERAPY; GENETIC VECTORS; HUMAN; SIMPLEXVIRUS;

EID: 0033814231     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Over-expression of heat shock protein 70 protects neuronal cells against both thermal and ischaemic stress but with different efficiencies
2. Transplantation of adrenal medulla tissue to striatum in Parkinsonism
3. Double transduction with GTP cytohydrolase I and tyrosine hydroxylase is necessary for spontaneous synthesis of L-DOPA by primary fibroblasts
4. Long term expression of a reporter gene from latent herpes simplex virus in the rat hippocampus
5. Heat shock proteins delivered with a virus vector can protect cardiac cells against apoptosis as well as against thermal or ischaemic stress
6. Transfer and expression of the lac Z gene in rat brain neurons by herpes simplex virus mutants
7. Gene delivery to cardiac cells in vitro and in vivo using herpes simplex virus vectors
8. Gene delivery to the central and peripheral nervous systems of mice using HSV1 ICP34.5 deletion mutant vectors
9. Pure populations of transduced primary human cells can be produced using GFP expressing herpes virus vectors and flow cytometry
10. Latent herpes simplex virus in human trigeminal ganglia. Detection of an immediate early gene anti-sense transcript by in situ hybridization
11. In vivo deletion analysis of the herpes simplex virus type 1 latency associated transcript promoter
12. A latent nonpathogenic HSV-1 derived vector stably expresses β galactosidase in mouse neurons
13. Gene transfer to neurons using herpes simplex virus-based vectors
14. In vivo expression of β-galactosidase in hippocampal neurons by HSV-mediated gene transfer
15. Survival and function of intrastriatally grafted primary fibroblasts genetically modified to produce L-dopa
16. A novel latency-associated promoter is continued within the herpes simplex virus type 1 UL flanking repeats
17. Gene therapy of murine motor neuron disease using adenoviral vectors for neurotrophic factors
18. β-galactosidase as a marker in the peripheral and neural tissues of the herpes simplex virus infected mouse
19. Herpes simplex virus latent RNA (Lat) is not required for latent infection in the mouse
20. High efficiency gene transfer to the central nervous system of rodents and primates using herpes virus vectors lacking functional ICP27 and ICP34.5
21. Herpes simplex virus type 1 vector mediated gene transfer to muscle
22. Potential use of herpes simplex virus (HSV) vectors for gene therapy of neurological disorders
23. Therapeutic potentials for glial cell line-derived neurotrophic factor (GDNF) based upon pharmacological activities in the CNS
24. Biology of glial cell line-derived neurotrophic factor (GDNF): Implications for the use of GDNF to treat Parkinson's disease
25. Molecular biology of herpes simplex virus latency
26. Herpes simplex virus vectors for gene therapy
27. Viral vectors and Parkinson's disease
28. Gene delivery to neurons: Is herpes simplex virus the right tool for the job?
29. Long term promoter activity during herpes simplex virus latency
30. Ex vivo Hepatic gene transfer in mouse using a defective herpes simplex virus-1 vector
31. Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence related sequences in Glasgow strain 17+ between immediate-early gene 1 and the 'a' sequence
32. Decreased reporter gene expression during latent infection with HSV LAT promoter constructs
33. Pathways of viral gene expression during acute neuronal infection with HSV-1
34. Perspectives in gene therapy
35. Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection
36. rhGDNF protects nigrostriatal DA neurons against the neurotoxin 6-OHDA: An in vivo study using microdialysis and positron emission tomography
37. Development and optimisation of herpes simplex virus vectors for multiple long term gene delivery to the peripheral nervous system
38. Herpes simplex virus mediated human hypoxanthine-guanine phosphoribosyl transferase gene transfer into neuronal cells
39. Therapeutic replication competent herpes virus
40. An inquiry into the mechanisms of herpes simplex virus latency
41. Herpes simplex virus type 1 ICP27 is an essential regulatory protein
42. RNA complementary to a herpes virus alpha gene mRNA is prominent in latently infected neurons
43. Equine herpes virus 1 gene 12 can substitute for Vmw65 in the growth of herpes simplex virus 1 (HSV1) allowing the generation of optimised cell lines for the propagation of vectors with multiple immediate-early gene defects
44. Protection of neuronal cells from apoptosis by hsp27 delivered with a herpes simplex virus-based vector
45. Intracerebral recombinant HSV-1 vector does not reactivate latent HSV-1
46. Trigeminal ganglion neurons are protected by the heat shock proteins hsp70 and hsp90 from thermal stress but not from programmed cell death following NGF withdrawal